Search results for " arthritis"

showing 10 items of 629 documents

Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa.

2018

INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease which has been associated with an increased risk of adverse cardiovascular (CV) outcomes. Adequate stratification of the CV risk is an issue of major importance in patients with HS. To analyze the usefulness of carotid ultrasound (US) assessment for the CV disease risk stratification compared with a traditional score, the Framingham risk score (FRS), in a series of patients with HS. METHODS: Cross-sectional study of 60 patients with HS without history of CV events, diabetes mellitus or chronic kidney disease. Information on CV risk factors was collected and the FRS was calculated. Thus, the patients were…

medicine.medical_specialtyanimal structuresCross-sectional studyEndocrine DisordersInflammatory DiseasesCardiologylcsh:MedicineBlood PressureDiseaseVascular MedicineBiochemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineMedicine and Health SciencesDiabetes MellitusMedicineHumansCoronary Heart DiseaseIn patientHidradenitis suppurativalcsh:Science030203 arthritis & rheumatologyMultidisciplinaryFramingham Risk Scorebusiness.industrylcsh:RBiology and Life SciencesHealth Risk Analysismedicine.diseaseAtherosclerosisLipidsHidradenitis SuppurativaHealth CareBlood pressureCarotid ArteriesCross-Sectional StudiesCholesterolROC CurveCardiovascular DiseasesMetabolic Disorderslcsh:QbusinessKidney diseaseResearch ArticlePLoS ONE
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Hautknoten und Ulzera der Extremitäten bei einem Patienten mit rheumatoider Arthritis

2002

CASE HISTORY: While being treated with corticosteroids and methotrexate for rheumatoid arthritis, a 63-year-old man developed livid nodules on his lower arms, hands and feet, as well as fever, necrotizing skin ulcers and rupture of a finger extensor tendon. INVESTIGATIONS: No vasculitis was found in a biopsy of one of the nodules on the lower arm. Fast growing mycobacteria, classified as M. marinum by PCR, were cultured from wound swabs. TREATMENT AND COURSE: The lesions healed on administration of ciprofloxacin, ethambutol and clarithromycin as well as local treatment. CONCLUSION: Cutaneous lesions of an atypical mycobacterial infection are often misdiagnosed. This is especially so in immu…

medicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industryGeneral MedicineSkin ulcerbacterial infections and mycosesmedicine.diseasebiology.organism_classificationDermatologyRheumatoid arthritisBiopsyPrednisolonemedicineDifferential diagnosismedicine.symptombusinessVasculitisMycobacterium marinumEthambutolmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

The heart in rheumatoid arthritis: contrasting or misleading data from clinical research? Comment on the article by Giles et al

2010

medicine.medical_specialtybusiness.industryImmunologyAlternative medicinemedicine.diseaseClinical researchRheumatologyRheumatoid arthritisImmunologyRheumatoid arthritis MRI echocardiography clinical researchmedicineImmunology and AllergyPharmacology (medical)Intensive care medicinebusiness
researchProduct

Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sec…

2021

Summary Background Presenting symptoms of childhood cancers might mimic those of rheumatic diseases. However, the evidence available to guide differential diagnosis remains scarce. Preventing wrong or delayed diagnosis is therefore important to avoid incorrect administration of glucocorticoid or immunosuppressive therapy and worsening of prognosis. As such, we aimed to assess the prevalence and characteristics of presenting musculoskeletal manifestations in patients at cancer onset and to identify the factors that differentiate childhood malignancies with arthropathy from juvenile idiopathic arthritis. Methods We did a multicentre, cross-sectional study at 25 paediatric haemato-oncology cen…

medicine.medical_specialtybusiness.industryImmunologyArthritisCancerOdds ratioMusculoskeletal manifestationJuvenile idiopathic arthritismedicine.diseaseHistiocytosisRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPrednisoneInternal medicineJoint painArthropathyMusculoskeletal manifestations childhood cancer juvenile idiopathic arthritismedicinechildhood cancerImmunology and AllergyDifferential diagnosismedicine.symptombusinessmedicine.drug
researchProduct

SAT0136 Focus on Implementation of Cardiovascular Risk Factor Recording for Patients with Rheumatoid Arthritis in A Rheumatology Outpatient Clinic

2014

Objectives There is a need for implementing the knowledge of cardiovascular (CV) risk in patients with rheumatoid arthritis (RA) into clinical practice. Our aim was to evaluate CV risk factor (CVRF) recording in a rheumatology outpatient clinic (ROC), where the standard was annual CVRF recording. A second aim was to compare CVRF recording between a regular ROC (RegROC) and an arthritis clinic (AC), which consisted of a structured, team-based model. Methods In 2012, 1142 RA patients visited the ROC of the Hospital of Southern Norway. Of these 612 attended RegROC and 530 attended AC. We conducted a search in the patients9 hospital records to identify recording of CVRFs. Results CVRFs were rec…

medicine.medical_specialtybusiness.industryImmunologyArthritisOdds ratiomedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyBlood pressureRheumatologyInternal medicineRheumatoid arthritismedicinePhysical therapyImmunology and AllergyOutpatient clinicIn patientRisk factorbusinessAnnals of the Rheumatic Diseases
researchProduct

AB1299-HPR THE RHEUMA-VOR APP: OPTIMIZING THE EARLY DIAGNOSIS OF RHEUMATIC DISEASES

2020

Background:The proof-of-concept network study “Rheuma-VOR” aims to improve the quality of rheumatological care through coordinated cooperation. In particular, rheumatic diseases should be diagnosed as early as possible and treated quickly in a targeted manner [3]. Smartphone apps have a potential to improve the management of chronic diseases. For example, they can be used to provide health information, or to offer self-monitoring and self-screening options [1, 2].Objectives:The Rheuma-VOR Screening-App study examines whether a smartphone-based app can increase the detection rate of the three most common chronic inflammatory rheumatic diseases: rheumatoid arthritis, psoriatic arthritis and s…

medicine.medical_specialtybusiness.industryImmunologyPsychological interventionmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyPsoriatic arthritisRheumatologyInternal medicineFamily medicineCohortmedicineEtiologyImmunology and AllergyMedical diagnosisbusinesscomputermHealthDelphicomputer.programming_languageAnnals of the Rheumatic Diseases
researchProduct

FRI0056 Joint damage in patients with rheumatoid arthritis over 15-20 years – are there differences between women and men?

2013

Background Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women and men meet remission criteria more often than women do. Long-term severity of RA can be analyzed from permanent joint damage in radiographs. Objectives To study possible differences in the extent of radiographic joint damage between women and men in four early RA cohorts with 15 or more years of prospective follow-up. Methods Early RA cohorts with prospective longitudinal observations include following cohorts: Jyvaskyla Central Hospital with 70 patients from 1990’s (JYV1990) and 135 patients from the 1980’s (JYV1980), Lund University Hospital with…

medicine.medical_specialtybusiness.industryImmunologySevere diseasemedicine.diseaseUniversity hospitalGeneral Biochemistry Genetics and Molecular BiologySurgeryRheumatologyRemission criteriaRheumatoid arthritisInternal medicineJoint damageEarly ramedicineImmunology and AllergyIn patientbusinessRheumatismAnnals of the Rheumatic Diseases
researchProduct

POS1021 THE PsABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INH…

2021

Background:There are still unmet needs in the treatment of psoriatic arthritis (PsA), including in terms of treatment persistence, which is a function of effectiveness, safety and patient satisfaction. Ustekinumab (UST) was the first new biologic drug to be developed for the treatment of PsA after tumour necrosis factor inhibitors (TNFi).Objectives:To compare treatment persistence, effectiveness and safety of UST and TNFi in Italian patients within the PsABio cohort.Methods:PsABio (NCT02627768) is an observational study of 1st/2nd/3rd-line UST or TNFi treatment in PsA in 8 European countries. The current analysis set includes 222 eligible patients treated in 15 Italian centres, followed to …

medicine.medical_specialtybusiness.industryImmunologySignificant differenceClinical diseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCurrent analysisUnmet needsPsoriatic arthritisRheumatologyInternal medicineUstekinumabTreatment persistenceImmunology and AllergyMedicineIn patientbusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct